Drug Trial Radar · NCT07229807
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Nov 22, 2025
Primary completion
Jan 17, 2026
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim of the trial is to investigate safety and efficacy of ZSP1273 granules
Conditions
- Influenza a
Interventions
ZSP1273Drug
Oral
OseltamivirDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Alleviation of SymptomsTime frame: DAY1~DAY15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Children Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.